Skip to main content
. 2022 Jan 31;24(8):1318–1330. doi: 10.1093/neuonc/noac024

Fig. 2.

Fig. 2

GRm13Z40-2 cells lack alloreactivity. Alloreactivity was tested using a 4-hour 51Cr-release assay with GRm13Z40-2 effectors against EBV-transformed lymphoblastic cell lines (LCL) generated from donors of different allogeneic HLA types (indicated in Table at right). TM-LCL-OKT3 targets expressed the CD3 agonist OKT3 and acted as a positive control.